Can myelodysplastic syndromes cause acute myeloid leukaemia?

Progression is possible, not inevitable. The likelihood differs according to the MDS subtype, blood counts, chromosome or gene findings, and the proportion of immature cells called blasts.

In MDS, the marrow makes blood cells abnormally and may produce too few functioning red cells, white cells or platelets. If the abnormal clone changes further, blasts can build up and crowd out healthy blood production. When diagnostic features meet the criteria for AML, the disease is reclassified and the treatment discussion changes.

Symptoms cannot establish that transformation has occurred. Fatigue, infections, bruising or bleeding can result from low blood counts in MDS itself, so clinicians compare blood tests over time and may use a bone marrow sample and molecular testing when results change.

Attend scheduled blood tests and haematology visits even when you feel well. Ask for a clear monitoring plan, including which blood-count changes might lead to an earlier appointment or another marrow examination. Take medicines as directed and tell the team before adding supplements or stopping treatment.

Keep a brief record of fever, infections, unusual bruising, bleeding, breathlessness and changes in energy. This does not diagnose AML, but it gives the team useful timing and context when deciding whether your counts or care plan need reassessment.

Follow your haematology team's urgent-contact instructions for fever or signs of infection, particularly while receiving treatment or when white blood cells are low. Seek urgent help for breathing difficulty, bleeding that does not stop, black stools, blood in vomit, sudden severe weakness or new confusion.

Arrange earlier review for increasing bruising, repeated nosebleeds, worsening tiredness, breathlessness, recurrent infections or a noticeable decline from your usual health. These changes have several possible causes and need blood tests rather than assumptions about progression.

Ask how your MDS subtype and test findings shape the monitoring schedule, what would prompt another marrow test, whether treatment aims to improve blood counts or alter disease progression, and whom to contact if symptoms arise between appointments.